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Angiotensin II receptor antagonists (angiotensin II receptor blockers; ARBs)Abstract
are a class of antihypertensive drugs that are generally considered comparable to
ACE inhibitors in the prevention of heart and kidney failure. However, these two
classes of agents do interfere in different stages of the renin-angiotensin system.
In patients with type 2 diabetes mellitus, advantages for ARBs over conventional
(non-ACE inhibitor) therapy on progression from micro- to macroalbuminuria
and overt nephropathy and end-stage renal disease have been shown in clinical
trials. In patients with type 2 diabetes and end-stage renal disease, the need for
dialysis and/or transplantation results in the use of major healthcare resources.
This paper reviews the available economic evidence on treatment with ARBs in
type 2 diabetic patients with advanced renal disease.
Within-trial analytic and Markov model economic evaluations of the
RENAAL (Reduction of Endpoint in Non-insulin dependent diabetes mellitus
with Angiotensin II Antagonist Losartan), IDNT (Irbesartan Diabetic Nephropa-
thy Trial) and IRMA (IRbesartan in type 2 diabetes with MicroAlbuminuria)-2
studies suggest that treatment with ARBs in patients with type 2 diabetes with
overt or incipient nephropathy confers health gains and net cost savings compared
with conventional (non-ACE inhibitor) therapy. For reimbursement and reference
pricing decisions, there is a need for a head-to-head comparison of an ACE
inhibitor with ARBs to model all possible costs and effects of ACE inhibitors and
ARBs. This will result in a proper pharmacoeconomic outcome, where both types
of drugs can be compared for healthcare decisions.
Angiotensin II receptor antagonists (angiotensin class of antihypertensives that are generally consid-
II receptor blockers; ARBs) are a relatively recent ered to have similar, or even greater (based on
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mechanism of action), efficacy than ACE inhibitors follow-up years.[11,12] US data show that 40% of new
for two major therapeutic areas: prevention of car- ESRD cases are caused by diabetes, with a great
diovascular and renal outcomes.[1] With respect to contribution to the total annual ESRD costs, estimat-
the latter, antihypertensive treatment to delay renal ed at approximately $US25 billion in 2002.[13]
disease progression is most effective when targeting This paper reviews the available pharmacoeco-
the renin-angiotensin system (RAS), i.e. using nomic evidence on treatment with ARBs in type 2
ARBs or ACE inhibitors. However, both classes do diabetic patients with advanced renal disease. Our
interfere at different stages of the RAS, clearly paper links to previous work published in this jour-
separating them from each other pharmacologically. nal concerning the prevention of such advanced
A major advantage for ARBs over ACE inhibi- stages of renal disease, and concluding that expen-
tors[2,3] is their better adverse drug reaction (ADR) sive interventions that have proved to be truly effec-
profile. tive may have a favourable pharmacoeconomic out-
come.[8] We also present some original data on theIn patients with type 2 diabetes mellitus, advan-
pharmacoeconomic implications of the RENAALtages for ARBs (added to standard antihypertensive
(Reduction of Endpoint in Non-insulin dependenttherapy, excluding ACE inhibitors) over amlodipine
diabetes mellitus with Angiotensin II Antagonistand placebo for progression from micro- to
Losartan) trial in The Netherlands.macroalbuminuria, overt nephropathy and end-stage
renal disease (ESRD) have been reported.[4-6] Re-
1. Diabetic Nephropathysults of these trials have led to ARBs being incorpo-
rated into evidence-based treatment guidelines, such
Diabetic nephropathy is characterised by persis-as those by the American Diabetes Association
tent and progressive loss of albumin via the urine.(ADA).[7] The ADA states that ARBs, next to ACE
Incipient diabetic nephropathy with microalbumin-inhibitors, are first-choice agents for treating ne-
uria involves the urinary excretion of 30–300mg ofphropathy in hypertensive diabetic patients.[7]
albumin in the urine per day (or 20–200 µg/min).In trials comparing ARBs with ACE inhibitors, Overt nephropathy with persistent macroalbumin-hard endpoints are either lacking or do not show
uria involves the excretion of >300 mg/day (>200
significant differences between the two drug classes. µg/min). In overt nephropathy, glomerular filtrationIn addition, more experience exists with ACE inhib-
rate steadily declines. This stage of overt nephropa-itors, and for some ACE inhibitors patents have thy will generally result in progression to renal
expired, making them relatively cheap and enhanc- failure, with its associated need for dialysis anding their pharmacoeconomic profile.[8,9] Both factors transplantation, but also to increasing cardiovascu-probably contributed to recommendations for ACE lar risk. It has been shown that elevated albuminuriainhibitors as first-choice agents in clinical guide- is associated with a higher risk for cardiovascularlines for the treatment of hypertension in diabetic
morbidity and mortality, independent of otherpatients, for example in the Dutch guidelines.[10]
‘classical’ risk factors such as hypertension, dys-Such guideline recommendations are equally appli- lipidaemia and smoking.[14] The association is even
cable to patients with type 2 diabetes and advanced
stronger for albuminuria than for these classical risk
renal disease, including macroalbuminuria, protein- factors.[15,16]
uria and overt nephropathy.
Obviously, delay in the progression of renal dis- 2. Clinical Trials of Angiotensin II
ease – and ultimately prevention of ESRD – may Antagonists (ARBs) in Type 2 Diabetes
result in financial benefits and health gains. ESRD with Overt Nephropathy
implies the need for dialysis and/or kidney trans-
plantation (both costly interventions) with often Several randomised clinical trials on ARBs in
scarce availability, and waiting list problems. Euro- patients with type 2 diabetes and nephropathy have
pean data suggest that dialysis costs around €60 000 been published recently.[4,5,17,18] Most notably – and
annually and transplantation €25 000–40 000 in the already economically evaluated – are RENAAL[4,19]
first year (2002 values), with lower costs in the and IDNT (Irbesartan Diabetic Nephropathy Tri-
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al).[5,20] Both these trials have shown that the ARBs 2.2 IDNT
confer renoprotective effects beyond what might be
IDNT involved 1715 patients with type 2 diabe-expected from the achieved blood pressure lower-
tes and nephropathy, and had three trial arms –ing. Here we discuss both trials and compare the
irbesartan, amlodipine and placebo – with all threeavailable information on ARBs with that on ACE
being added to conventional therapy.[5] All patientsinhibitors for the specific patient group of type 2
were hypertensive (blood pressure >135/85mm Hgdiabetes with overt nephropathy. In section 3 some
or on antihypertensive treatment). Average patientadditional trials on ARBs, notably IRMA-2
follow-up was almost 3 years. As in RENAAL,(IRbesartan MicroAlbuminuria diabetes type 2 pa-
patients receiving ACE inhibitors were switched totients),[6] and one major trial in cardiology with a
other antihypertensive therapy prior to inclusion.subgroup analysis for type 2 diabetes patients (LIFE
Reported outcomes for irbesartan were relative[Losartan Intervention For Endpoint reduction in
risk reductions for the composite endpoint (death,hypertension]) are discussed.[21]
ESRD or doubling of serum creatinine level) of 19%
and 24% compared with placebo and amlodipine,
2.1 RENAAL respectively. The relative risk reduction for ESRD
was 23%, for both irbesartan versus amlodipine and
versus placebo, although these reductions were notRENAAL,[4] a randomised placebo-controlled
statistically significant. The absolute risks for ESRDtrial in 1513 patients with type 2 diabetes and ne-
of irbesartan, amlodipine and placebo were 14%,phropathy, compared the efficacy of losartan versus
18% and 18%, respectively. There were no signifi-placebo (added to conventional antihypertensive
cant differences between treatments in the rates oftherapy [diuretics, calcium channel antagonists, α-
death from any cause or in the cardiovascular com-and β-adrenoceptor antagonists, centrally acting
posite endpoint (including cardiovascular death,agents or any combination, excluding ACE inhibi-
myocardial infarction and heart failure).tors]). One of the primary endpoints was ESRD or
Patients in the irbesartan group had significantlythe need for dialysis. Patients on ACE inhibitors at
fewer adverse events per 1000 days of treatmentbaseline had this medication withdrawn prior to
than those in the placebo and amlodipine groupsrandomisation. RENAAL was discontinued, slightly (p = 0.002). However, serious hyperkalaemia result-
earlier than planned, as soon as the results of the ing in the discontinuation of treatment occurredHOPE (Heart Outcomes Prevention Evaluation) tri-
more often in the irbesartan group (p = 0.01 for both
al[22,23] indicated superiority of ACE inhibitors over
comparisons).placebo (additional to conventional therapy) in
averting cardiovascular events in renally impaired
2.3 Commentspatients. Cardiovascular morbidity and mortality
was specified as a secondary endpoint in RENAAL.
Both RENAAL and IDNT report positive effica-
In RENAAL, a relative risk reduction of losartan cy for ARBs in delaying ESRD, with fairly similar
for ESRD was estimated at 28% (p = 0.002) on the levels of relative risk reduction at 23–28%. When
basis of the Cox regression model. Crude absolute published, these results were highly relevant, as no
risks for ESRD of losartan and placebo were 20% previously published studies with hard endpoints on
and 26%, respectively. No statistically significant renal disease progression existed for ACE inhibitors
differences between losartan and placebo were in type 2 diabetic patients with nephropathy. Previ-
found for overall mortality and cardiovascular mor- ously, it had been shown that ACE inhibitors were
bidity and mortality. For RENAAL, cardiovascular beneficial for type 1 diabetic patients with nephrop-
morbidity and mortality prognosis was found to be athy, but this patient group differs in various aspects
better in patients with higher reductions of albumi- from type 2 diabetics (for example concerning dem-
nuria levels whether in the placebo (conventional ographic and metabolic factors).[26] In both
therapy) or losartan group.[24,25] RENAAL and IDNT,[4,5] the advantages of ARBs
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
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exceeded those attributable to reductions in blood al included patients with a blood pressure <180/
pressure. 105mm Hg at baseline; i.e. normotensive or moder-
In both trials, patients who were on ACE inhibi- ately hypertensive. Patients (n = 332) were
tors prior to the study were switched to the studied randomised to valsartan or amlodipine. Patients re-
drugs (ARBs) or placebo. In the literature, it has ceiving other hypertensive agents were switched to
been suggested that discontinuation of ACE inhibi- the drugs under investigation. Endpoints in the study
tors for washout before a trial could have potential were defined by albuminuria levels: percentage
effects on risk reductions.[27] A subgroup analysis of change in urinary albumin excretion and proportion
RENAAL patients showed that relative risk reduc- of patients returning to healthy albuminuria levels
tions were rather similar between patients both pre- (<20 µg/min). Whereas similar changes in blood
viously and not previously receiving ACE inhibitors pressure were seen between treatments, valsartan(close to the 28% average for both groups [29% for lowered albuminuria significantly more than
those previously on ACE inhibitors vs 27% for those amlodipine (reductions of 44% and 8%, respective-
not]).[28] This indicates that the switch away from ly; p < 0.001). Further, the proportion of patientsACE inhibitors will not have influenced the findings
returning to normoalbuminuria was greater for val-
relevantly. Ideally, trials will be designed directly
sartan than for amlodipine (30% and 15%, respec-
comparing both groups of drugs: ARBs versus ACE
tively; p < 0.001).inhibitors.[27]
For newer ARBs – candesartan, olmesartan and
3.2 Type 2 Diabetes in General; LIFE Substudyeprosartan – large clinical trials in patients with type
2 diabetes are not yet available.[29-31]
The LIFE trial was conducted among 9193 par-
3. Other Trials on ARBs ticipants aged ≥55 years with hypertension and left
ventricular hypertrophy, among whom were 1195
Other trials, discussed in the following subsec- patients with type 2 diabetes, with 11% having
tions, have evaluated ARBs in patients with type 2 clinical albuminuria at baseline.[21,33] The trial – with
diabetes in stages of renal dysfunction that come a mean follow-up of 4.8 years – was designed to
prior to overt nephropathy, in particular show the beneficial effects of losartan compared
microalbuminuria. with conventional antihypertensive therapy on left
ventricular hypertrophy (a strong independent risk
3.1 Incipient Nephropathy factor for cardiovascular morbidity and mortality).
Overall, it was found that losartan prevented more
3.1.1 IRMA-2 cardiovascular morbidity and mortality than ate-
In the IRMA-2 study, 590 patients with type 2 nolol with, in particular, a statistically significant
diabetes, hypertension and microalbuminuria (urine effect on stroke (risk reduction of 25% for losartan
albumin excretion of 20–200 µg/min) were compared with atenolol; p = 0.001). In the diabetes
randomised to receive irbesartan, either 150mg or substudy,[33] the same conclusions were reached;
300mg, or placebo once daily.[6] After 2 years, the losartan seems to have benefits beyond blood pres-
endpoint of overt diabetic nephropathy was reached sure reduction and decreasing albuminuria levels.
in 14.9% of placebo-treated participants, and in Additionally, development of microalbuminuria9.7% and 5.2% of those receiving irbesartan 150mg
was reported significantly (p = 0.002) less often inand 300mg, respectively (relative risk reductions of
the losartan group than in the atenolol group. The39% and 70%, respectively).[6]
prevalence of microalbuminuria in the diabetes sub-
study fell in the losartan group from 11% at baseline3.1.2 MARVAL
to 8% after approximately 5 years versus only aThe MARVAL (MicroAlbuminuria Reduction
small reduction from 12% to 11% in the atenololwith VALsartan) study was also performed in type 2
group.[33]diabetic patients with microalbuminuria.[32] This tri-
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
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4. ACE Inhibitors in Type 2 Diabetes 5. Pharmacoeconomic Analyses
The methodology for economic evaluation ofHOPE and EUROPA (EURopean trial On reduc-
clinical trials is developing quickly. Various meth-tion of cardiac events with Perindopril in stable
ods are now available, including the application of
coronary Artery disease)[23,34] showed that ACE in- Fieller’s method, bootstrap approaches and assum-hibitors provide significant reductions in cardiovas- ing a bivariate normal distribution for mean costs
cular morbidity and mortality versus placebo among
and effects.[39] Even short-term Markov models maypatients with cardiovascular risk factors. Both stud- be applied to the economic evaluation of clinicalies included a large group of type 2 diabetes pa- trials.[40] The advantages are that the data used are
tients. all trial-based and only a limited number of assump-
A subanalysis of the HOPE study on patients tions may be required. Some of the clinical trials
with type 2 diabetes has been published.[22] It described in sections 2–4 have been subject to such
showed that ramipril protects against nephropathy trial-based economic analysis. A major limitation of
compared with placebo, when added to standard such analyses is the relatively short time frame,
which does not extend beyond the clinical trial peri-antihypertensive (other blood pressure-lowering
od. For reimbursement studies, long-term analysesdrugs) therapy. In addition, a beneficial effect of
are often required.[41] For that purpose, long-termramipril was detected for diabetic patients on the
Markov models are used.[40] An example of such acomposite endpoint of myocardial infarction, stroke
model is provided in figure 1.and death from cardiovascular causes, with a rela-
In the following sections, we take a closer look attive risk of approximately 0.76 (95% CI 0.65,
the economics of the RENAAL, IDNT and IRMA-20.92).[22] As such, the HOPE study adequately com-
studies. These results are summarised in table I.bined nephrological and cardiovascular endpoints in
type 2 diabetes patients.
5.1 RENAALA further substudy of HOPE among diabetic
patients explicitly investigated cardiovascular risks
5.1.1 USAin relation to the nephrological marker albuminu-
RENAAL[4] has been economically evaluatedria.[35] The results indicated that the risk for cardio-
from a US healthcare perspective.[19] The analysisvascular events increases with increasing albuminu-
included all direct costs related to the study medica-ria levels. Therefore, the authors concluded that
tion and direct benefits of delayed dialysis costsscreening for albuminuria identifies people at high (although a few transplantations occurred in the
risk for cardiovascular complications.
The BENEDICT (The BErgamo NEphrologic
DIabetes Complications Trial) study[36] examined
whether ACE inhibitors and non-dihydropyridine
calcium channel antagonists, alone or in combina-
tion, prevented microalbuminuria (20–200 µg/min)
in patients with hypertension, type 2 diabetes, and
healthy albuminuria levels. Results showed that pa-
tients using ACE inhibitors were less likely to pro-
gress to microalbuminuria than those receiving cal-
cium channel antagonists.
Further subanalyses for type 2 diabetes are
planned, e.g. the PERTINENT (PERindopril-
Thrombosis, InflammatioN, Endothelial dysfunc-
tion and neurohormonal Activation Trial), a sub-




















Fig. 1. General Markov model (1-year cycle) for the progression of
renal disease in type 2 diabetic patients. Transition probabilities
were estimated based on the UKPDS (United Kingdom Prospective
Diabetes Study).[40,42] ESRD = end-stage renal disease.
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Table I. Results of published pharmacoeconomic evaluations of clinical trials for angiotensin II receptor antagonists (ARBs) in patients with
type 2 diabetes mellitus and renal disease
Study and country ARB Maximum Discount rate (% per annum) Net cost savings per patient
follow-up (y) costs effects [year of value]
RENAAL
US[19] Losartan 4 3 NM $US3522 vs placeboa (3.5y follow-up)
[2001]
The Netherlands[43] Losartan 3.5 4 4 €4540 vs placeboa [2003]
IDNT
US[20] Irbesartan 25 3 3 $US23 817 vs amlodipine
$US16 026 vs placeboa (10y follow-up)
$US26 290 vs amlodipine
$US15 607 vs placeboa (25y follow-up)
[2000]
Belgium[12] Irbesartan 10 3 3 €15 000 vs amlodipine
€9000 vs placeboa [2002]
France[12] Irbesartan 10 3 3 €20 000 vs amlodipine
€13 000 vs placeboa [2002]
Germany[44] Irbesartan 10 5 5 €14 000 vs amlodipine
€9000 vs placeboa [2001]
UK[45] Irbesartan 10 6 1.5 £5125 vs amlodipine
£2919 vs placeboa [2003]
IRMA-2
US[46] Early and late 25 3 3 Early irbesartan treatment:
irbesartanb $US11 922 vs controla
Late irbesartan treatment: $US3252 vs
controla [2000]
Spain[47] Early 25 3 3 Early irbesartan treatment:
irbesartan €11 082 vs controla [2002]
a Conventional therapy but not ACE inhibitors.
b Based on IRMA-2 linked to IDNT.
IDNT = Irbesartan Diabetic Nephropathy Trial; IRMA = IRbesartan in type 2 diabetes with MicroAlbuminuria; RENAAL = Reduction of
Endpoint in Non-insulin dependent diabetes mellitus with Angiotensin II Antagonist Losartan; NM = not mentioned in the paper.
trial, all days with ESRD were assumed as dialysis phropathy could be expected to lead to a reduction
of 9.2 person-years with ESRD over 3.5 years.[19]costs). Additionally, health effects were considered
The authors concluded that “Treatment within terms of avoided ESRD days during the trial. For
losartan in patients with type 2 diabetes and ne-the initial analysis, dialysis costs, losartan treatment
phropathy, thus also resulted in substantial cost sav-and ESRD days were evaluated at various periods of
ings,” which corresponds with findings in the studypatient follow-up. Monetary amounts in $US, year
of Alexander et al.[49] and the European study of2001 values, were discounted at 3%, according to
Gerth et al.[50] The authors of RENAAL propose thatthe US guidelines.[48]
this holds for the US situation and for patient groups
The study indicated clear potentials for cost sav- that are comparable to those in RENAAL. To be
ings to be achieved with losartan, increasing with relevant, we add that cost savings should also persist
longer periods of patient follow-up. Net cost savings within an analysis that uses a longer time frame than
through averted ESRD days were achieved after the within-trial analysis allows. All these limitations
losartan treatment for 2–2.5 years (break-even are discussed in section 6.
point). After 4 years of patient follow-up, net sav-
ings were estimated at $US5300 per patient (95% CI 5.1.2 Europe
950, 9600; p = 0.017). Additionally, the authors Information was obtained from the manufacturer
calculated that the addition of losartan to the treat- of losartan[28] and local health economics sources,
ment of 100 patients with type 2 diabetes and ne- enabling the investigation of the pharmacoeconomic
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
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implications of RENAAL on European, Asian, ESRD for secondary analysis. Simulations were run
South American and Canadian markets. for a cohort of 1000 type 2 diabetes patients with
nephropathy over their remaining lifetime. Half-The within-trial analysis conducted from the
cycle corrections were made.[40]Dutch healthcare perspective showed potential for
Table II shows that application of the Markovcost savings with losartan. These cost savings in-
model with RENAAL assumptions indicates in-creased with longer patient follow-up to €4540 per
creasing net savings with increasing period of analy-patient after 3.5 years (2003 values; discount rate
sis. Long-term savings are almost 4-fold those in the4% according to Dutch guidelines;[51] annual
short term. For validating the Markov model welosartan costs approximately €400; annual dialysis
note that predicted short-term per patient savings arecosts €63 000).[43]
similar to those measured in the within-trial analy-Further analysis for The Netherlands was con-
sis. Finally, the table illustrates that the Markovducted by our group, developing a Markov model
model did not reproduce short-term net savings ifdescribing the crucial transitions between disease
Dutch clinical guideline[10] assumptions were insert-states and using the cost data for losartan and dialy-
ed into the model. However, in the long-term, netsis as specified above. Our model was an adaption of
savings were also estimated using these assump-one used previously,[52] which focused on the out-
tions, which were previously assumed to best reflectcome parameters nephropathy, ESRD and death. As
the progression of the Dutch type 2 diabetes patient.previously stated, the primary advantage of a
It should be noted that the current model lacks theMarkov model is that it enables investigation of
inclusion of renal transplantation. Inclusion of thesepotential developments beyond the limited trial ho-
data might alter the results slightly, though we dorizon (for example, development of ESRD in pa-
not expect major changes in results and conclusions.tients in whom ESRD was successfully delayed
beyond the trial horizon and who survived long
5.2 IDNTenough to still develop ESRD). Furthermore, it pro-
vides a more flexible tool to vary assumptions than
5.2.1 USAthe within-trial analysis.
A specific within-trial analysis has not been pub-Annual transition probabilities for albuminuria
lished for the IDNT. However, such an analysisstages were derived from the RENAAL trial by
from the healthcare perspective has been performedcounting person-years in stages and relating these to
as a part of a longer term Markov model analysis forannual transitions. These rates were reported in the
the US ($US, year 2000 values), including threeoriginal publication.[4] Death rate in ESRD was tak-
treatment strategies (irbesartan, amlodipine and pla-en from van Os et al.[11] Transition probabilities for
progression to ESRD on losartan and placebo were
inserted in the model (derived from both arms of
RENAAL). The difference between both options
determined potential cost savings. In RENAAL, the
mean number of days with ESRD was 31% lower in
the losartan-treated group than in the placebo-treat-
ed group after approximately 3.5 years. Next to this,
the during-trial progression to ESRD was 37%. This
is relatively high compared with previous estimates
at 0.5–4% per year for progression to ESRD in type
2 diabetes patients with nephropathy.[53,54] Also, in
the framework of clinical treatment guideline devel-
opment, this lower rate was previously suggested for
Dutch type 2 diabetic patients with nephropathy.[10]
Therefore, a lower annual transition rate without
losartan at 1.6% was assumed for progressing to
Table II. Estimated cost savings per patient, calculated from the
healthcare perspective, of adding losartan (vs placebo) to standard
antihypertensive therapy in overt diabetic nephropathy type 2 dia-
betes patients, using a Markov Model (1-year cycle) with transition
probabilities from (i) RENAAL[19] or (ii) the Dutch Clinical Guide-
lines[10]
Time horizon (y) Cost savingsa (€b)
RENAAL[19,43] CBO[10]
3.5 4 540 –330
7 11 400 780
25 16 800 4 260
a Negative cost savings indicate net costs.
b Year 2003 values.
CBO = Centraal Begeleidings Orgaan voor de intercollegiale
Toetsing, Utrecht, The Netherlands (clinical guideline for Dutch
medical specialists); RENAAL = Reduction of Endpoint in Non-
insulin dependent diabetes mellitus with Angiotensin II Antagonist
Losartan.
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cebo) and five outcome parameters: (i) nephropathy; amlodipine and placebo, respectively, over the
(ii) doubling of serum creatinine level; (iii) ESRD 10-year period. These results were found robust
managed with dialysis; (iv) ESRD managed with under a large range of plausible assumptions in the
transplantation; or (v) death.[20] Transition probabili- sensitivity analysis.
ties within the Markov model were taken from the The German study employed country-specific
clinical trial; US values were used and discounted at prices (2001 values), a time horizon of 10 years and
3%. The short-term analysis based on the Markov discounting at 5% per annum. It was found that for
model and limited to the mean period of patient German ‘IDNT-like’ patients, the cumulative inci-
follow-up of approximately 3 years indicated cost dence of ESRD would be lower on irbesartan (36%)
savings for irbesartan treatment compared with both than on amlodipine (49%) or placebo (45%). Addi-
amlodipine and placebo. Compared with placebo, tionally, irbesartan was estimated to save costs of
irbesartan conferred health gains in terms of days or €14 000 and €9000 per patient versus amlodipine
years of life gained. Health effects for amlodipine or placebo, respectively, over the 10-year period.
and irbesartan over placebo were very similar, with For the UK, a time horizon of 10 years and
a slight benefit for amlodipine. discount rates for costs (2003 values) and effects of
Extension of the time horizon of the Markov 6.0% and 1.5%, respectively, were used. Delay in
model changed this slight benefit in health gains for onset of ESRD with irbesartan led to cost savings of
amlodipine and increased health gains for £5125 and £2919 per patient and improvements in
irbesartan. Table I illustrates that cost savings for discounted life expectancy of 0.07 and 0.21 over 10
irbesartan reach their maximum somewhere be- years versus amlodipine and control, respective-
tween 10 and 25 years (in fact at 15 years), while ly.[45]
health gains keep improving (not shown in table I). In short, applications of the Markov model to
The authors concluded that “this Markov model European countries reaffirms the findings for the
predicted that irbesartan would increase life expec- US: irbesartan appears to save costs and confer
tancy and decrease costs of care in patients with type health gains for type 2 diabetes patients with ne-
2 diabetic nephropathy. Based on these results, phropathy.
irbesartan could have the potential to substantially
reduce the clinical and economic burdens of patients
5.3 IRMA-2
with type 2 diabetic nephropathy.”
5.2.2 Europe 5.3.1 USA
Three studies have been published – based on the Cost effectiveness for RAS intervention in the
IDNT and using the Markov model developed for phase of incipient nephropathy (IRMA-2) has been
the US using the healthcare perspective – providing studied in relation to the IDNT study (PRIME; PRo-
evidence for the favourable pharmacoeconomic im- gram for Irbesartan Mortality and morbidity Evalua-
pact of irbesartan in European settings. These stud- tions) using 2002 cost levels.[5,6,8,46] Through linking
ies pertain to Belgium and France,[12] Germany[44] these studies it could be investigated whether it is
and the UK.[45] more cost effective to start with irbesartan at the
For Belgium and France, country-specific prices stage of overt nephropathy or prior to that stage, in
(2002 values), a 10-year time horizon and 3% dis- particular in incipient nephropathy. The initial prob-
counting were employed. Onset of ESRD was lem was that IDNT and IRMA-2 did not link directly
delayed an additional 1.5 years for irbesartan versus to each other. In particular, patients leaving IRMA-2
amlodipine and placebo. During the 10-year period, because of the diagnosis of nephropathy had a medi-
this delay in ESRD translated into gains of 0.13 life- an urinary albumin excretion of 700 mg/day versus
years for irbesartan versus amlodipine and 0.26 life- almost 2000 mg/day for patients entering IDNT. In
years versus placebo. Irbesartan provided cost sav- terms of progression of disease, this means that there
ings of €15 000 and €9000 per patient in Belgium, is a gap of approximately 2–3 years between the two
and €20 000 and €13 000 in France, versus trials.
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To close the gap between the two studies, a state at 3%): $US28 782 for conventional therapy,
of early nephropathy was created in a Markov model $US16 859 for early irbesartan and $US25 529 for
(figure 2). Baseline transition probabilities in the late treatment. Cost savings were as follows:
Markov model were directly derived from the place- $US11 922 for early irbesartan, $US3252 for late
bo arms of IRMA-2 and IDNT and corrected for the irbesartan versus conventional treatment and
estimated relative risks of treatment with irbesartan $US8670 for early versus late irbesartan. The break-
300mg daily: 0.30 (95% CI 0.14, 0.61) in IRMA-2 even point for early and late irbesartan versus con-
and 0.83 (95% CI 0.62, 1.11) in IDNT.[46] The ventional treatment was reached after approximately
confidence intervals were used in probabilistic anal- 10 and 5 years, respectively.[46]
ysis using Monte-Carlo methods with a period of
5.3.2 Europeanalysis of 25 years in each simulation.
Three studies based on IRMA-2 have also pro-
Results were calculated for the US healthcare vided evidence for the favourable pharmacoeco-
payer perspective with dialysis costs of $US60 133 nomic impact of irbesartan in the for Spanish, Swed-
and costs of irbesartan at $US573.05 annually.[46] ish and Swiss settings.[47,55] In patients with hyper-
Starting with irbesartan in the microalbuminuric tension, microalbuminuria and type 2 diabetes, early
stage would avert >2 years spent with ESRD per treatment with irbesartan reduced the incidence of
patient compared with conventional treatment (other ESRD, extended life and led to cost savings in these
antihypertensive drugs excluding ACE inhibitors). three different European settings. Only the analysis
However, starting irbesartan treatment during ne- for Spain was published as a full research article.
phropathy would only avert 146 days spent with For that reason, only the Spanish results are further
ESRD per patient. The mean life expectancies described below.
would be 13 years on conventional therapy, 15 years The same Markov model as used for the US (see
for starting irbesartan in early nephropathy, and 13 section 5.3.1) was used to simulate and analyse the
years for late treatment. Cumulative incidence of situation in Spain. For the analyses from the third-
ESRD over 25 years would be 20% on conventional party healthcare payer perspective, country-specific
therapy, 7% with early intervention of irbesartan, costs, a 25-year time horizon and 3% discounting
and 16% if irbesartan was applied later, i.e. only were used. Early treatment with irbesartan led to
during overt nephropathy. Additionally, cost sav- 0.88 avoided years of ESRD. During the 25-year
ings were estimated for early treatment with period, discounted life expectancy was improved by
irbesartan. Total costs per patient were (discounted 0.84 years, with corresponding per patient cost-
savings of €11 082 versus conventional therapy.
6. Discussion
Recent clinical trials have presented the first evi-
dence on hard endpoints with respect to significant
reductions in progression to ESRD with ARBs in
type 2 diabetes patients with nephropathy
(RENAAL and IDNT).[4,5] These trials were evalu-
ated economically in both the short- and the long-
term, using within-trial analytic and Markov model
techniques for the US and European set-
tings.[12,19,20,43-47,49,50,52-55] Results and conclusions
were unequivocal: these drugs appear to confer both
health gains and net cost savings compared with
conventional (non-ACE inhibitor) therapy, i.e. they
are dominant therapies. Additionally, the economic










Fig. 2. Markov model for the analyses of IRMA-2 (IRbesartan in
type 2 diabetes with MicroAlbuminuria) and IDNT (Irbesartan Dia-
betic Nephropathy Trial).[13] The estimated transition probabilities
from IRMA-2 and IDNT changed from year to year, thus no single
value could be indicated in this model.[20,46] ESRD = end-stage
renal disease.
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would be cost effective to start ARB treatment even vascular and survival benefit with ACE inhibitors
prior to the overt nephropathy stage. but not with ARBs in patients with diabetic ne-
phropathy. The trials with ACE inhibitors were pla-Whether ACE inhibitors confer similar benefits
cebo controlled without equal blood pressure con-in these patient groups is as yet unknown, but not
unlikely given the related pharmacological proper- trol, resulting in a blood pressure difference in fa-
ties of the two drug classes and circumstantial evi- vour of ACE inhibitor treatment, whereas the ARB
dence. Apart from the DETAIL (Diabetics Exposed trials were actively controlled (vs standard therapy)
to Telmisartan And enalaprIL) trial, in which telmis- with the objective being to obtain equal blood pres-
artan was found to be not inferior to enalapril in sure control. This indirect comparison of ACE in-
providing renoprotection in type 2 diabetes patients, hibitors with ARBs also raises the need for a head-
there are hardly any head-to-head trials comparing to-head comparison and possibly a combination of
ARBs and ACE inhibitors.[56] two different agents from each class to study effects
Despite the absence of hard endpoint measure- on renal and cardiovascular outcomes, adverse ef-
ments on renal function for ACE inhibitors in type 2 fects[63,64] (i.e. dry cough and angio-oedema) and
diabetes, pharmacoeconomic analysis has been per- mortality. If effects of ACE inhibitors and ARBs do
formed based on clinical trials with intermediate not differ significantly, costs of drugs involved be-
endpoints.[57,58] These clinical trials were used by come more important for reimbursement deci-
Golan et al.[52] to estimate progression rates in a sions.[65] As the first ACE inhibitors are now off
Markov model developed to investigate the cost patent, this would favour this class of drugs. The
effectiveness of ACE inhibitors in the treatment and DETAIL study[56] showed equivalence in renal pro-
screening of type 2 diabetes. The additional net costs tection between ACE inhibitors and ARBs in pa-
for treating all hypertensive diabetic patients with tients with early diabetic nephropathy. This would
ACE inhibitors would be $US7500 per QALY suggest lower costs for ACE inhibitor treatment in
gained compared with screening for microalbumin- type 2 diabetic patients with nephropathy. Unfortu-
uria first and treating only those in whom it was
nately, the DETAIL study[56] lacks pharmacoeco-detected.
nomic evidence and is not completely transferable to
Further evidence has been published on favour- all patients with type 2 diabetes and nephropathy.
able cardiovascular outcomes for ARBs, among There is a need for further investigation on theboth type 2 diabetes patients and non-diabetics. For impact of patent expiries and subsequent cost conse-
example, the recent LIFE trial showed that losartan quences.
was associated with a significant reduction in car-
Long-term ‘real-world’ analyses are often re-diovascular mortality among almost 1200 patients
quired in national guidelines for ‘good pharma-with type 2 diabetes included in the trial, and provid-
coeconomic practice’ in supporting clinical guide-ed a significant reduction in the incidence of diabe-
line development or reimbursement decisions.[14,15]tes among 8000 participants with hypertension.[33,59]
Despite sophisticated methods having been devel-In economic evaluations of studies such as LIFE,
oped for analysing economic data in clinical trialsARBs have been shown to be potentially cost effec-
(including Fieller’s method, bootstrapping and pow-tive in type 2 diabetic patients with nephropathy.
er calculations for economic outcomes), such analy-Comparable studies also exist for ACE inhibitors,
ses are increasingly considered non-optimal givenfor example the economic evaluation of HOPE for
the lack of long-term and ‘real-world’ perspec-Germany [60] and Sweden.[61] However, none of
tives.[2] On the other hand, decision makers feelthese studies explicitly addressed cost effectiveness
in patients with type 2 diabetes in relation to albumi- uncomfortable with making healthcare payment de-
nuria levels. cisions based on models with time horizons up to 25
years. Also, in the IRMA-2/IDNT model, break-In the systematic review by Strippoli et al.,[62]
even is obtained ‘only’ after 6 years, which may stillsimilar effects on renal outcomes were found for
be considered longer than the typical time horizon ofARBs and ACE inhibitors. There is a point of dis-
some decision makers.cussion in this meta-analysis suggesting a cardio-
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Positive results from the IRMA-2/IDNT zon taking all costs and effects (renal and cardiovas-
model[46] have been published or presented now for cular, mortality and adverse effects) into account.
about ten countries.[66] The same conclusions are
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the results were sensitive to the number of ESRD All authors participated in the concept and design of thepatients treated by dialysis and the yearly cost of paper; analysis and interpretation of data; drafting or revision
dialysis. If there is a reduction in the latter cost in the of the manuscript. The authors have no conflicts of interest to
declare.future, the net savings obtained with irbesartan must
The authors acknowledge the work of G.W. Carides andbe revised. Another issue in the transferability of
W.C. Gerth (Merck & Company, Blue Bell, Pennsylvania,such results over various countries is that the rate of USA) on adapting the RENAAL trial-based pharmacoeco-progression from nephropathy to doubling of serum nomic model for losartan to the Dutch situation. M.J. Postma
creatinine level, or the earlier progression from and L.J.P. Annemans previously received grant support for
economically evaluating ARBs by MSD (Haarlem, Themicroalbuminuria to nephropathy, may be different
Netherlands), and Sanofi-Synthelabo (Paris, France), respec-among countries, because of not only ethnic aspects
tively.but also current management of patients, which is
No sources of funding were used to assist in the prepara-
often less optimal than the management in the place- tion of this study.
bo and active arms of the IRMA-2/IDNT study.[46]
In summary, multi-country adaption models based References
on existing (multi-country) trials are a good oppor- 1. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition ver-
sus angiotensin receptor blockade: which is better for renal andtunity to calculate cost effectiveness based on so-
cardiovascular protection? J Am Soc Nephrol 2004; 15: S64-phisticated models and can be easily used by several 70
countries. Despite this advantage, there are still local 2. Postma MJ, Kruidhof H, de Jong-van den Berg LT, et al.
Pharmacoeconomic aspects of losartan treatment to delay pro-imperfections for such models that are mostly relat-
gression of renal disease in patients with type 2 diabetes.
ed to demographic factors and differences in popula- Expert Opin Pharmacother 2003; 4 (9): 1543-50
3. Coyle JD, Gardner SF, White CM. The renal protective effectstions (i.e. race). Reimbursement agencies often re-
of angiotensin II receptor blockers in type 2 diabetes mellitus.quire analyses that are specifically tailored to their Ann Pharmacother 2004; 38: 1731-8
own country, e.g. evaluations of national screening 4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan
on renal and cardiovascular outcomes in patients with type 2programmes.[67]
diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective
7. Conclusions effect of the angiotensin-receptor antagonist irbesartan in pa-
tients with nephropathy due to type 2 diabetes. N Engl J Med
2001; 345 (12): 851-60Economic evaluations of RENAAL, IDNT and
6. Parving HH, Lehnert H, Bro¨chner-Mortensen J, et al. The effectIRMA-2 using different time horizons suggest
of irbesartan on the development of diabetic nephropathy in
ARBs versus conventional therapy to be cost saving patients with type 2 diabetes. N Engl J Med 2001; 345 (12):
870-8in type 2 diabetes patients with nephropathy, largely
7. American Diabetes Association. Standards of medical care inbecause of the high costs of dialysis and transplanta- diabetes. Diabetes Care 2005; 28 Suppl. 1: S4-36
8. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in thetion. Cost savings are seen within about 6 years. It is
prevention of diabetic nephropathy. Pharmacoeconomicsunusual to have an effective new treatment that may 2004; 22 (1): 9-28
also be cost saving. Even in secondary prevention 9. van Hout B, Simeon GP, McDonnell J, et al. Economic evalua-
tion of benazepril in chronic renal insufficiency. Kidney Inttrials such as the 4S (Scandinavian Simvastatin Sur-
1997; 52 (63): S159-62
vival Study) on simvastatin in a group of high-risk 10. van Ballegooie E, van Everdingen JJE. CBO guidelines on
diagnosis, treatment, and prevention of complication in diabe-patients, only a quarter of the treatment costs were
tes mellitus, retinopathy, foot ulcers, nephropathy and cardio-earned back through cost savings.[68]
vascular diseases: Dutch Institute for Quality Assurance [in
The economic profile of ACE inhibitors in this Dutch]. Nederlands Tijdschrift voor Geneeskunde 2000; 144
(9): 413-8particular patient group has still to be elucidated. For
11. van Os N, Niessen LW, Bilo HJ, et al. Diabetes nephropathy in
reimbursement decisions and reference pricing clas- the Netherlands: a cost-effectiveness analysis of national
clinical guidelines. Health Policy 2000; 51: 135-47sifications, a head-to-head trial comparing ACE in-
12. Palmer AJ, Annemans L, Roze S, et al. An economic evaluationhibitors with ARBs is needed, next to building a of irbesartan in the treatment of patients with type 2 diabetes,
pharmacoeconomic model with a proper time hori- hypertension and nephropathy: cost-effectiveness of Irbesartan
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
534 Boersma et al.
in Diabetic Nephropathy Trial (IDNT) in the Belgian and 34. Fox KM. Efficacy of perindopril in reduction of cardiovascular
French settings. Nephrol Dial Transplant 2003; 18: 2059-66 events among patients with stable coronary artery disease:
randomised, double-blind, placebo-controlled, multicentre tri-13. USRDS annual data report 2004. Bethesda (MD): National
al (the EUROPA study). The EURopean trial On reduction ofInstitutes of Health/National Institute of Diabetes and Diges-
cardiac events with Perindopril in stable coronary Artery dis-tive and Kidney Diseases, 2004
ease investigators. Lancet 2003; 362: 782-814. Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin
35. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk ofexcretion predicts cardiovascular and noncardiovascular mor-
cardiovascular events, death, and heart failure in diabetic andtality in general population. Circulation 2002; 106: 1777-82
nondiabetic individuals. JAMA 2001; 286: 421-615. Diercks GFH, Hillege HL, van Boven AJ, et al.
36. Ruggenenti P, Fassi A, Ilieva AP, et al. PreventingMicroalbuminuria modifies the mortality risk associated with
microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351electrocardiographic ST-T segment changes. J Am Coll Cardi-
(19): 1941-51ol 2002; 40 (8): 1401-7
37. Gomma AH, Fox KM. The EUROPA trial: design, baseline16. Asselbergs FW, Hillege HL, van Gilst WH. Framingham score
demography and status of the substudies. The EUROPA inves-and microalbuminuria: combined future targets for primary
tigators. Cardiovasc Drugs Ther 2001; 15: 169-79prevention? Kidney Int 2004; 66 Suppl. 92: S111-4
38. Ferrari R, Arbustini E, Blann A, et al. PERTINENT (PER-17. Ruilope LM, Segura J. Losartan and other angiotensin II antago-
indopril-Thrombosis, InflammatioN, Endothelial dysfunctionnists for nephropathy in type 2 diabetes mellitus: a review of
and Neurohormonal activation Trial): a sub-study of the EU-the clinical trial evidence. Clin Ther 2003; 25 (12): 3044-64
ROPA Study. Cardiovasc Drugs Ther 2003; 17: 83-9118. Zanella MT, Ribiero AB. The role of angiotensin II antagonism
39. Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside thein type 2 diabetes mellitus: a review of renoprotection studies.
box: recent advances in the analysis and presentation of uncer-Clin Ther 2002; 24 (7): 1019-34
tainty in cost-effectiveness studies. Annu Rev Public Health19. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces 2002; 23: 377-401the costs associated with diabetic end-stage renal disease: the
40. Briggs A, Sculpher M. An introduction to markov modelling forRENAAL study economic evaluation. Diabetes Care 2003; 26:
economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-683-7
40920. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness
41. International Society for Pharmacoeconomics & Outcomes Re-of irbesartan in the treatment of hypertensive type 2 diabetic
search (ISPOR). Pharmacoeconomic guidelines around thenephropathy. Clin Ther 2003; 25 (7): 2102-19
world [online]. Available from URL: http://www.ispor.org/21. Dahlo¨f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular PEguidelines/index.asp [Accessed 2005 Jun 30]
morbidity and mortality in the Losartan Intervention For 42. Adler AI, Stevens RJ, Manley SE, et al. Development andEndpoint reduction in hypertension study (LIFE): a random- progression of nephropathy in type 2 diabetes: the Unitedized trial against atenolol. Lancet 2002; 359: 995-1003 Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int22. Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on 2003; 63: 225-32
cardiovascular and microvascular outcomes in people with 43. Postma MJ, Bartstra J, Annemans LJP. Angiotensin-II antago-diabetes mellitus: results of the HOPE study and MICRO-
nists in diabetes mellitus type 2 [in Dutch]. Pharm WeekblHOPE substudy. Lancet 2000; 355: 253-9 2004; 139 (33): 1060-323. Yusuf S, Sleight P, Dagenais G, et al. Effects of an angiotensin- 44. Palmer AJ, Annemans L, Roze S, et al. Health economic conse-
converting-enzyme inhibitor, ramipril, on cardiovascular quences of the use of irbesartan in patients in Germany with
events in high-risk patients. N Engl J Med 2000; 342 (3): 145- type 2 diabetes, nephropathy and hypertension [in German].53 Dtsch Med Wochenschr 2004; 129: 13-824. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a 45. Palmer AJ, Annemans L, Roze S, et al. An economic evaluationtherapeutic target for cardiovascular protection in type 2 dia-
of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in abetic patients with nephropathy. Circulation 2004; 110: 921-7 UK setting. J Hum Hypertens 2004; 18 (10): 733-825. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target 46. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness offor renoprotection in patients with type 2 diabetic nephropathy:
early irbesartan treatment versus control (standard an-lessons from RENAAL. Kidney Int 2004; 65: 2309-20 tihypertensive medications excluding ACE inhibitors, other
26. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angioten- angiotensin-2 receptor antagonists, and dihydropyridine calci-
sin-converting-enzyme inhibition on diabetic nephropathy. um channel blockers) or late irbesartan treatment in patients
N Engl J Med 1993; 329 (20): 1456-62 with type 2 diabetes, hypertension, and renal disease. Diabetes
27. Huston P, Peterson R. Withholding proven treatment in clinical Care 2004; 27: 1897-903
research. N Engl J Med 2001; 345: 912-4 47. Palmer AJ, Annemans L, Roze S, et al. Irbesartan is projected to
28. Data on file, Merck & Co., Inc. 2003 be cost and life saving in a Spanish setting for treatment of
29. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its patients with type 2 diabetes, hypertension, and
use in essential hypertension. Drugs 2002; 62 (8): 1253-87 microalbuminuria. Kidney Int 2005; 67 Suppl. 93: S52-54
30. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 48. Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effective-
(8): 1345-53 ness in health and medicine. New York: University Press, 1996
31. Ruilope L, Ja¨ger B. Eprosartan for the treatment of hyperten- 49. Alexander CM, Lyle PA, Keane WF, et al. Losartan and the
sion. Expert Opin Pharmacother 2003; 4: 107-14 United States costs of end-stage renal disease by baseline
albuminuria in patients with type 2 diabetes and nephropathy.32. Viberti G, Wheeldon NM. Microalbuminuria reduction with
Kidney Int 2004; 66 Suppl. 92: S115-7valsartan in patients with type 2 diabetes mellitus: the
MicroAlbuminuria Reduction With VALsartan (MARVAL) 50. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the
study investigators. Circulation 2002; 106: 672-8 burden and cost of ESRD: public health implications from the
RENAAL study for the European Union. Kidney Int 2002; 6233. Lindholm LH, Ibsen H, Dahlo¨f B, et al. Cardiovascular morbidi-
(82): S68-72ty and mortality in patients with diabetes in the Losartan
Intervention for Endpoint reduction hypertension study 51. College voor zorgverzekeringen (CvZ). Guidelines for
(LIFE): a randomised trial against atenolol. Lancet 2002; 359: pharmacoeconomic research [in Dutch]. Amstelveen: College
1004-10 voor zorgverzekeringen, 1999
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
ARBs in Type 2 Diabetes with Nephropathy 535
52. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of 61. Bjo¨rholt I, Andersson FL, Kahan T, et al. The cost-effectiveness
treating all patients with type 2 diabetes with angiotensin- of ramipril in the treatment of patients at high risk of cardio-
converting enzyme inhibitors. Ann Intern Med 1999; 131 (9): vascular events: a Swedish sub-study to the HOPE study.
660-7 J Intern Med 2002; 251: 508-17
53. Eastman RC, Javitt JC, Herman WH, et al. Model of complica- 62. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin
tions of NIDDM: I. Model construction and assumptions. converting enzyme inhibitors and angiotensin II receptor an-
Diabetes Care 1997; 20 (5): 725-34 tagonists on mortality and renal outcomes in diabetic nephrop-
54. Eastman RC, Javitt JC, Herman WH, et al. Model of complica- athy: systematic review. BMJ 2004; 329: 828-31
tions of NIDDM: II. Analysis of the health benefits and cost- 63. Pylypchuk GB. ACE-inhibitor versus angiotensin II blocker
effectiveness of treating NIDDM with the goal of normog-
induced cough and angioedema. Ann Pharmacother 1998; 32:lycemia. Diabetes Care 1997; 20 (5): 735-44
1060-6
55. Palmer AJ, Roze S, Valentine WJ, et al. Irbesartan is projected 64. Fuchs SA, Meyboom RHB, van Puijenbroek EP, et al. Use ofto be cost and life saving compared to standard blood pressure
angiotensin receptor antagonists in patients with ACE-inhibi-control alone for treatment of patients with type 2 diabetes,
tor induced angiodema. Pharm World Sci 2004; 26: 191-2hypertension, and microalbuminuria in Spanish, Swedish and
Swiss settings [abstract]. Value Health 2004; 7 (6): 655 65. Mitch WE. Treating diabetic nephropathy: are there only eco-
nomic issues? N Engl J Med 2004; 351 (19): 1934-656. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor
blockade versus converting-enzyme inhibition in type 2 diabe- 66. Palmer AJ, Rodby RA. Health economics studies assessing
tes and nephropathy. N Engl J Med 2004; 351 (91): 1952-61 irbesartan use in patients with hypertension, type 2 diabetes,
and microalbuminuria. Kidney Int 2004; 66 Suppl. 92: S118-57. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of
angiotensin-converting enzyme inhibition on plasma creati- 120
nine and on proteinuria in normotensive type II diabetic pa- 67. Atthobari J, Asselbergs FW, Boersma C, et al. Cost-effective-
tients. Ann Intern Med 1993; 118: 577-81
ness of screening for albuminuria and subsequent treatment
58. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate with ACE-inhibitor to prevent cardiovascular events: a
decline in renal function in normotensive, normoalbuminuric pharmacoeconomic analysis linked to the PREVEND and
patients with type 2 diabetes mellitus: a randomized controlled PREVEND-IT studies. The PREVEND-IT study group. Clin
trial. Ann Intern Med 1998; 128: 982-8 Ther 2006; 28 (3): 432-44
59. Lindholm LH, Dahlo¨f B, Edelman JM, et al. Effect of losartan 68. Johannesson M, Jo¨nsson B, Kjekhus J, et al. Cost-effectiveness
on sudden cardiac death in people with diabetes: data from the
of simvastatin treatment in lower cholesterol levels in patientsLIFE study. Lancet 2003; 362: 619-20
with coronary heart disease. N Engl J Med 1997; 336: 332-6
60. Scha¨dlich PK, Brecht JG, Rangoonwala B, et al. Cost-effective-
ness of ramipril in patients at high risk for cardiovascular
events: economic evaluation of the HOPE (Heart Outcomes Correspondence and offprints: Cornelis Boersma, Antonius
Prevention Evaluation) study for Germany from the statutory
Deusinglaan 1, 9713 AV Groningen, The Netherlands.health insurance perspective. Pharmacoeconomics 2004; 22
E-mail: C.Boersma@rug.nl(15): 955-73
 2006 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2006; 24 (6)
